for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Cortexyme Provides Regulatory Update For COR388 Development Program In Alzheimer’S Disease

Feb 13 (Reuters) - Cortexyme Inc:

* CORTEXYME PROVIDES REGULATORY UPDATE FOR COR388 DEVELOPMENT PROGRAM IN ALZHEIMER’S DISEASE

* CORTEXYME INC - INTERIM ANALYSIS IN PHASE 2/3 GAIN TRIAL EXPECTED TO OCCUR IN Q4 2020

* CORTEXYME INC - CORTEXYME CONTINUES TO EXPECT GAIN TRIAL’S FINAL ANALYSIS IN Q4 OF 2021. Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up